Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Read more...
Read More Details
Finally We wish PressBee provided you with enough information of ( Eli Lilly was hoping for even greater weight loss drug demand )
Also on site :
- Über das Spiel hinaus: Haier Vision für Jugend und Nachhaltigkeit
- Scandinavia’s Nuclear Waste Revolution
- Men have hundreds more saved in ‘rainy day’ funds than women, research indicates